Target intelligence / Profile preview

N-linked galactose-terminated glycan

Molecular classification
Glycan, N-linked glycan, Carbohydrate modification, Cell surface glycan
01

Overview

N-linked galactose-terminated glycans are a class of carbohydrates covalently attached to the asparagine (N) residue of proteins, predominantly on the cell surface. The primary structure consists of a core N-glycan to which various sugars—including galactose—are added, with galactose serving as a "terminal" sugar moiety. These terminal galactose residues play a critical role in cell–cell interactions, protein folding, and as binding sites for pathogens such as the AAV9 vector, which uses these glycans for cell entry. Alterations in the pattern of terminal galactose are associated with diseases such as cancer, immune disorders, and infection, but these structures are not themselves discrete and classically druggable molecular targets—they reflect a modification shared across many proteins and cell types.

Other names
N-glycan with terminal galactoseN-glycosylated galactose (cell surface)Terminal galactose N-linked glycan
02

Biological functions

Cell–cell recognition and adhesionProtein folding and quality control in the ER and GolgiModulation of immune cell trafficking and functionRegulating receptor endocytosis and cell signalingPathogen (virus, bacteria, toxin) attachment factorDetermining protein stability, solubility, and localization
03

Disease associations

Infection (e.g., viral entry by adeno-associated virus serotype 9/AAV9)Cancer (altered cell-surface glycosylation in malignant transformation)Immune disorders (self/non-self recognition, autoimmunity)Metabolic disease (protein glycosylation defects in diabetes)
04

Safety considerations

Broad targeting of terminal galactose on N-glycans could affect many cell types, risking off-target effects and immune reactivityAlteration of glycan processing can impact protein folding and trafficking, with potential toxicities
05

Biomarkers

Aberrant N-glycan galactosylation is used as a biomarker in congenital glycosylation disorders or some cancers (not universally applied, context-dependent)

Beyond the preview

Go deeper on N-linked galactose-terminated glycan.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on N-linked galactose-terminated glycan.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call